Pfizer stock analysis
Pfizer passes 3 of 7 fundamental tests, a score of 4/10. On the daily chart it is in an uptrend, RSI 70, 1% below its 52-week high: uptrend, no fresh entry: wait for a pullback or breakout. Its own volatility puts the likely range at $27.81–$31.46 a month from now and $23.89–$36.62 in a year (68% bands). The last two days of news lean bearish (1 positive, 1 negative stories).
Fundamentals 4/10
- Market cap
- $168.6 B
- P/E · forward
- 38.9 · 10.2
- PEG · P/B
- 13.6 · 2.0
- ROE · net margin
- +5% · +7%
- Revenue · earnings growth
- +3% · —
- Debt / equity
- 74%
- Dividend · beta
- 5.8% · 0.3
- Next results
- 3 Nov 2026
- ✕ ROE above 15%
- ✕ Net margin above 10%
- ✕ Revenue growing over 10%
- ✓ Debt/equity under 100%
- ✓ Positive free cash flow
- ✓ Forward P/E under trailing (earnings expected up)
- ✕ PEG under 2
Swing technicals (daily)
- Trend
- up · 50d above 200d
- RSI(14)
- 70
- 20 / 50 / 200-day avg
- $28.34 / $27.97 / $26.56
- 20-day breakout
- above $29.88 · below $27.12
- ATR(14)
- $0.55 (1.9% a day)
- 52-week range
- $23.62 – $29.88
- Return 3m · 6m · 1y
- +20% · +7% · +21%
What the price could do
| In | Likely range (68%) |
|---|---|
| 1 mo | $27.81 – $31.46 (-6% / +6%) |
| 3 mo | $26.59 – $32.91 (-10% / +11%) |
| 6 mo | $25.44 – $34.40 (-14% / +16%) |
| 1 year | $23.89 – $36.62 (-19% / +24%) |
Analysts (26): buy, mean target $29.26 (-1%)
From its own volatility (21% a year), no drift assumed: what its swings allow, not a forecast.
Pfizer news · last two days
News lean: Bearish · 1 up · 1 down- 1h agoPfizer or Kraft Heinz: Only One Gets My Dividend Dollars for the Next 10 YearsTIKR
- 22h agoPfizer Just Declared Its 352nd Straight Quarterly Dividend. Is the 6% Yield Safe?Motley Fool
- 25h agoNovavax Plunges 12% as Selloff Hits Vaccine Makers; Moderna Tumbles 10%, Pfizer Holds Steady24/7 Wall St.
- 26h agoWhat to Expect From Pfizer's Q3 2026 Earnings ReportBarchart
- 26h agoModerna Tumbles 10% as Profit Taking Hits Cancer Vaccine Rally; BioNTech Eases, Pfizer Stays Put24/7 Wall St.
- 37h agoTukysa Approval Might Change The Case For Investing In Pfizer Stock (PFE)Simply Wall St.
- 45h agoPfizer vs. AbbVie: Is the Cheaper Pharma Stock Really the Better Investment?Insider Monkey
- 2d agoModerna Rallies 6% as Money Rotates Into Healthcare; BioNTech and Pfizer Edge Higher24/7 Wall St.
- 2d agoAbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?Motley Fool
- 3d agoWhy Did GME, BMBL, PFE Stocks Hit 52-Week Highs Today?Stocktwits
Its order flow and footprint, the AI read of every headline, the expected move, and your own holdings beside it, with your broker connected.
Information and analytics for education only, not investment advice or a recommendation to buy or sell. Alephix Intelligence is not registered with SEBI as an investment adviser or research analyst. Prices may be delayed; figures come from public market data.